Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
Angela ChoJeong-Yeol ParkShin Wha LeeDae-Yeon KimDae Shik SuhJong-Hyeok KimYong-Man KimYoung-Tak KimPublished in: Archives of gynecology and obstetrics (2021)
Olaparib maintenance treatment in BRCA-mutated recurrent ovarian cancer is effective and safe in clinical practice. Most recent PFI, response to the last platinum-based chemotherapy, and the number of previous chemotherapy lines were associated with PFS in patients with BRCA-mutated recurrent ovarian cancer.